Atomoxetine-associated Raynaud’s phenomenon in children: an under-recognized risk of non-stimulant ADHD therapy
Authors:
Open Access
- 11 November 2026
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 1968909
Abstract
Raynaud’s phenomenon (RP) is an increasingly recognized yet still underreported adverse effect of ADHD pharmacotherapy. Whereas stimulant-associated RP is well documented, atomoxetine-related RP has surfaced only in isolated pediatric cases, leaving a gap in our understanding of non-stimulant toxicity. This narrative review reports the first Asian pediatric case identified in English- and regional-language literature and synthesizes the global evidence base, integrating five pediatric cases, targeted literature retrieval, and disproportionality analyses of FAERS and WHO VigiBase. Atomoxetine carries a consistent pharmacovigilance signal for RP. Beyond the elevation of synaptic cleft norepinephrine, the five cases point to suspected contributors: plasma drug concentration, CYP2D6-mediated metabolic variability—particularly relevant in East Asian populations—and individual susceptibility with superimposed triggers. Onset latency is highly variable (hours to years), and the course in reported cases is milder and fully reversible, without digital ulceration, features consistent with, though not determined by, the sustained, gradual peripheral noradrenergic elevation produced by selective norepinephrine transporter inhibition, in contrast to the rapid catecholamine surges typical of stimulants. These findings call for longitudinal vigilance beyond the titration phase, prompt exclusion of secondary causes, and systematic pharmacovigilance reporting.Keywords
This publication has 38 references indexed in Scilit:
- Drug‐Induced Raynaud's Phenomenon and Underlying Mechanism: A Disproportionality Analysis From the World Health Organization Pharmacovigilance DatabaseArthritis & Rheumatology, 2026
- Raynaud Syndrome Associated with Medication for Attention-Deficit/Hyperactivity Disorder: A Systematic ReviewCNS Drugs, 2025
- From neurons to brain networks, pharmacodynamics of stimulant medication for ADHDNeuroscience & Biobehavioral Reviews, 2024
- Systemic sclerosis induced by CNS stimulants for ADHD: A case series and review of the literatureAutoimmunity Reviews, 2020
- Raynaud’s phenomenon—an update on diagnosis, classification and managementClinical Rheumatology, 2019
- Learning from the past and looking to the future: Emerging perspectives for improving the treatment of psychiatric disordersEuropean Neuropsychopharmacology, 2015
- Cardiovascular Effects of Methylphenidate, Amphetamines and Atomoxetine in the Treatment of Attention-Deficit Hyperactivity Disorder: An UpdateDrug Safety, 2014
- Association between treatment with central nervous system stimulants and Raynaud's syndrome in children: A retrospective case–control study of rheumatology patientsArthritis & Rheumatism, 2008
- Signal that reboxetine use is linked with symptoms of peripheral ischaemia (Raynaud's syndrome)European Journal of Clinical Pharmacology, 2003
- Novel halogenated analogs of tomoxetine that are potent and selective inhibitors of norepinephrine uptake in brainNeurochemistry International, 1995